DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 203567
NDA 203567 describes JUBLIA, which is a drug marketed by Bausch and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug and one Paragraph IV challenge. Additional details are available on the JUBLIA profile page.
The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.
The generic ingredient in JUBLIA is efinaconazole. There are fourteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the efinaconazole profile page.
Summary for 203567
| Tradename: | JUBLIA |
| Applicant: | Bausch |
| Ingredient: | efinaconazole |
| Patents: | 9 |
| Formulation / Manufacturing: | see details |
Generic Entry Opportunity Date for 203567
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 203567
Suppliers and Packaging for NDA: 203567
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567 | NDA | Valeant Pharmaceuticals North America LLC | 0187-5400 | 0187-5400-02 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0187-5400-02) > 2 mL in 1 BOTTLE, WITH APPLICATOR |
| JUBLIA | efinaconazole | SOLUTION;TOPICAL | 203567 | NDA | Valeant Pharmaceuticals North America LLC | 0187-5400 | 0187-5400-04 | 1 BOTTLE, WITH APPLICATOR in 1 CARTON (0187-5400-04) > 4 mL in 1 BOTTLE, WITH APPLICATOR |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;TOPICAL | Strength | 10% | ||||
| Approval Date: | Jun 6, 2014 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 6, 2019 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ➤ Sign Up | Patent Expiration: | Jul 8, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ➤ Sign Up | Patent Expiration: | Oct 5, 2021 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS | ||||||||
Complete Access Available with Subscription
